Hedman Partners advised ARTeSYN BioSolutions in connection with its sale to Repligen

ARTeSYN BioSolutions (“ARTeSYN”) was sold to Repligen Corporation for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock.

Over the past decade, ARTeSYN Biosolutions has established downstream processing leadership with a suite of state-of-the-art single-use systems for chromatography, filtration, continuous manufacturing, and media/buffer prep workflows. 

Repligen Corporation is a company devoted to the development and production of materials used in the manufacture of biological drugs. Repligen is also listed on the NASDAQ exchange under the symbol RGEN.

Hedman Partners has advised ARTeSYN’s Estonian subsidiary Artesyn Biosolutions Estonia OÜ for many years and assisted ARTeSYN’s lead counsel Peter Taylor from Peter Taylor Law in this sale transaction in matters pertaining to Estonian law, including with the preparation of shareholder resolutions and other corporate documentation, and termination of employment and management board member agreements.

The client was advised by managing partner Merlin Seeman and associate Kristel Tael-Same.